BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21559715)

  • 1. Mechanism-related circumvention of Cisplatin resistance in human ovarian-carcinoma cells by (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanediacarboxylato)-platinum (ii) monohydrate and modulation of its sensitivity by 12-o-tetradecanoylphorbol-13-acetate.
    Isonishi S; Ochiai K; Yasuda M; Ohkawa K; Terashima Y
    Int J Oncol; 1994 Dec; 5(6):1309-14. PubMed ID: 21559715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells.
    Isonishi S; Ohkawa K; Tanaka T; Howell SB
    Br J Cancer; 2000 Jan; 82(1):34-8. PubMed ID: 10638963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometric analyses of the characteristics of tumor cells treated with two platinum compounds: 1,1-cyclobutanedicarboxylato(2-aminomethylpyrrolidine)- platinum(II) and cisplatin.
    Inoue S; Mizuno S; Ito M; Ohnuma T
    Jpn J Cancer Res; 1992 Nov; 83(11):1231-40. PubMed ID: 1483936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
    Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
    Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity and cellular accumulation of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)platinum( II) monohydrate, in cisplatin-sensitive and -resistant murine P388 leukemia cells.
    Kamisango K; Matsumoto T; Akamatsu K; Morikawa K; Tashiro T; Koizumi K
    Jpn J Cancer Res; 1992 Mar; 83(3):304-11. PubMed ID: 1582895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activities of new platinum compounds, DWA2114R, NK121 and 254-S, against human leukemia cells sensitive or resistant to cisplatin.
    Kobayashi H; Takemura Y; Miyachi H; Ogawa T
    Invest New Drugs; 1991 Nov; 9(4):313-9. PubMed ID: 1804804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interactions of (-)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato)platinum(II) monohydrate (DWA2114R) and related compounds with deoxyribonucleic acid.
    Morikawa K; Matsumoto T; Matsuoka Y; Koizumi K
    Chem Pharm Bull (Tokyo); 1992 Jan; 40(1):212-9. PubMed ID: 1576676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antitumor activity of a new platinum complex, DWA2114R against human tumor cell lines.
    Akamatsu K; Saito H; Tsunenari T; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
    Anticancer Res; 1993; 13(6A):2261-5. PubMed ID: 8297143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent antitumour activity of (-)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato)platinum(II) monohydrate (DWA2114R) against advanced L1210 leukaemia in mice.
    Akamatsu K; Endo K; Matsumoto T; Kamisango K; Morikawa K; Koizumi M; Koizumi K
    Br J Cancer; 1992 Nov; 66(5):827-32. PubMed ID: 1419625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells.
    Misawa T; Kikkawa F; Maeda O; Obata NH; Higashide K; Suganuma N; Tomoda Y
    Jpn J Cancer Res; 1995 Jan; 86(1):88-94. PubMed ID: 7737915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the antitumour effects and nephrotoxicity-inducing activities of two new platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato+ ++)-platinum (II) monohydrate, and its enantiomeric isomer.
    Matsumoto T; Endoh K; Akamatsu K; Kamisango K; Mitsui H; Koizumi K; Morikawa K; Koizumi M; Matsuno T
    Br J Cancer; 1991 Jul; 64(1):41-6. PubMed ID: 1854626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new anticancer platinum compound, (-)-(R)-2-aminomethyl-pyrrolidine(1,1-cyclobutanedicarboxylato) platinum(II): DNA interstrand crosslinking, repair and lethal effects in normal human, Fanconi's anaemia and xeroderma pigmentosum cells.
    Fujiwara Y; Nakamura M; Yokoo S
    Br J Cancer; 1993 Jun; 67(6):1285-92. PubMed ID: 8512813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicological and tumoricidal evaluations of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato+ ++)platinum( II) monohydrate, in rats.
    Akamatsu K; Endo K; Matsumoto T; Morikawa K; Koizumi M; Koizumi K; Mitsui H
    Jpn J Cancer Res; 1991 Jun; 82(6):724-31. PubMed ID: 1906857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of sensitivity to platinum(II)-containing drugs by 12-O-tetradecanoyl-phorbol-13-acetate in a human ovarian carcinoma cell line.
    Isonishi S; Hom DK; Eastman A; Howell SB
    Br J Cancer; 1994 Feb; 69(2):217-21. PubMed ID: 8297717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accumulation of cis-diamminedichloroplatinum (II) and its analogues in sensitive and resistant human ovarian carcinoma cells.
    Misawa T; Kikkawa F; Oguchi H; Morikawa Y; Kawai M; Maeda O; Iwata M; Kano T; Furuhashi Y; Tomada Y
    Oncology; 1992; 49(3):173-9. PubMed ID: 1495742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo antineoplastic activity of a new platinum antineoplastic agent, (R)-(-)-1,1-cyclobutanedicarboxylate (2-aminomethylpyrrolidine)-platinum (II) (DWA2114R) on freshly separated human tumor cells and human tumor xenografts transplanted in nude mice--a comparison with cis-diammine-dichloroplatinum (CDDP).
    Nio Y; Imai S; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Tobe T
    Anticancer Res; 1991; 11(2):761-7. PubMed ID: 2064331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination therapy of a new platinum complex, DWA2114R with various antitumor agents against mouse tumors in vivo].
    Akamatsu K; Endo K; Tsunenari T; Matsumoto T; Kaiho S; Morikawa K; Koizumi M; Mitsui H; Koizumi K
    Gan To Kagaku Ryoho; 1992 Feb; 19(2):229-35. PubMed ID: 1736835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells.
    Minagawa Y; Kigawa J; Ishihara H; Itamochi H; Terakawa N
    Jpn J Cancer Res; 1994 Sep; 85(9):966-71. PubMed ID: 7961127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
    Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of treatment schedule of an antitumor platinum complex, DWA2114R, on the antitumor activity].
    Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
    Gan To Kagaku Ryoho; 1992 Feb; 19(2):223-8. PubMed ID: 1736834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.